Neuroimaging Studies of the Treatment of Bipolar Depression With Citalopram
| Status: | Completed |
|---|---|
| Conditions: | Depression, Psychiatric |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 64 |
| Updated: | 3/9/2019 |
| Start Date: | April 2010 |
| End Date: | December 2013 |
Regional metabolic changes associated with response to 6 weeks of citalopram treatment, using
18-Fluorodeoxyglucose Positron Emission Tomography imaging, will be characterized (FDG PET).
18-Fluorodeoxyglucose Positron Emission Tomography imaging, will be characterized (FDG PET).
Regional metabolic changes associated with response to 6 weeks of citalopram treatment, using
18-Fluorodeoxyglucose Positron Emission Tomography imaging, will be characterized (FDG PET).
The following hypothesis will be tested: Antidepressant response or remission in depressed
BPD patients will be associated with changes in cortical (prefrontal, parietal, premotor) and
paralimbic (hippocampus, anterior cingulate, subgenual cingulate, posterior cingulate, and
anterior insula) regions, consistent with SRI antidepressant response in unipolar depressed
patients.
18-Fluorodeoxyglucose Positron Emission Tomography imaging, will be characterized (FDG PET).
The following hypothesis will be tested: Antidepressant response or remission in depressed
BPD patients will be associated with changes in cortical (prefrontal, parietal, premotor) and
paralimbic (hippocampus, anterior cingulate, subgenual cingulate, posterior cingulate, and
anterior insula) regions, consistent with SRI antidepressant response in unipolar depressed
patients.
Inclusion Criteria:
- Current age 18-64 years; DSM-IV diagnosis of BPD, type-I, or type-II; Enrolled in the
Citalopram Study at Tufts Medical Center
Exclusion Criteria:
- Current pregnancy, or inability to utilize contraception, The presence of any metallic
implants, History of claustrophobia
We found this trial at
1
site
Click here to add this to my saved trials
